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1646Prognostic Significance of FDG-PET in Relapsed or
Refractory Classical Hodgkin Lymphoma Treated with
Standard Salvage Chemotherapy and Autologous Stem
Cell Transplantation
Jacob P. Smeltzer,1 Amanda F. Cashen,1 Qin Zhang,2 Andrew Homb,3 Farrokh Dehdashti,3
Camille N. Abboud,1 John F. DiPersio,1 Keith E. Stockerl-Goldstein,1 Geoffrey L. Uy,1 Ravi Vij,1
Peter Westervelt,1 Nancy L. Bartlett,1 Todd A. Fehniger118Positron emission tomography using [ F]fluorodeoxyglucose (FDG-PET) has emerged as the standard re-
sponse assessment tool in frontline therapy for classical Hodgkin lymphoma (cHL). The ability of FDG-
PET to predict outcomes in patients with relapsed cHL treated with modern standard salvage chemotherapy
and autologous stem cell transplantation (ASCT) remains uncertain. Forty-six patients with relapsed/refrac-
tory cHL treated from 2001 to 2007 with standard salvage/ASCT therapy had FDG-PETavailable for blinded
review. The results of pre-ASCT FDG-PET interpreted by the international harmonization project (IHP) cri-
teriawere compared with published prognostic models for prediction of event-free survival (EFS) and overall
survival (OS). Overall, 3-year EFS was 62% and OS was 78%, with a median follow-up of 38 months. Pre-
ASCT FDG-PET response significantly predicted 3-year EFS in FDG-PET-negative (82%) versus FDG-PET-
positive (41%) patients (P 5 .02). A trend was observed for 3-year OS comparing FDG-PET-negative
(91%) versus -positive (64%) patients (P 5 .08). Multivariate analysis demonstrated the independent
prognostic significance of pre-ASCT FDG-PET for EFS with a hazard ratio (HR) of 3.2 (confidence interval
[CI] 1.1-9.0, P 5 .03). Pre-ASCT FDG-PET scans predict EFS in patients with relapsed cHL patients treated
with modern salvage/ASCT therapy and warrant prospective evaluation.
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The clinical development of combination chemo-
therapy has dramatically improved outcomes in classi-
cal Hodgkin lymphoma (cHL) over the past several
decades. Patients with advanced-stage cHL have a
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line chemotherapy [1]. Despite these improvements,
a substantial number of cHL patients relapse or have
primary refractory disease. The currently accepted
therapy for relapsed/refractory cHL is standard-dose
salvage chemotherapy followed by high-dose chemo-
therapy and autologous stem cell transplantation
(ASCT) in chemosensitive patients, which results in
long-term disease-free survival (DFS) for 50% to
60% of patients [2-5]. Pre-ASCT identification of re-
lapsed cHL patients who have a poor prognosis despite
ASCT would help direct higher-risk patients to inves-
tigational therapies. Retrospectively, numerous pre-
ASCT prognostic factors have been assessed and
clinical risk models developed in an effort to predict
subsequent response to ASCT [6-10]. However,
there is wide variability in the significance of clinical
and laboratory factors between different studies. A
simple risk stratification method is needed to
improve prognostication and clinical trial design for
relapsed/refractory cHL patients.
Biol Blood Marrow Transplant 17:1646-1652, 2011 1647Prognostic Significance of FDG-PETPositron emission tomography using [18F]fluoro-
deoxyglucose (FDG-PET) has emerged as the imaging
tool of choice to assess responses in cHL to frontline
chemotherapy [11], and it is now included in the
standard response assessment of lymphoma patients
[12,13]. We analyzed the impact of pre-ASCT FDG-
PET on clinical outcomes in 46 relapsed/refractory
cHL patients. These patients were uniformly treated
with standard salvage chemotherapy followed by
ASCT, and pre-ASCT FDG-PET was blindly inter-
preted using the published international harmoniza-
tion project PET criteria [12].PATIENTS AND METHODS
Patients
Between January 2001 and December 2007, 106
consecutive patients with relapsed or refractory cHL
were treated at Washington University School of
Medicine with high-dose chemotherapy followed by
ASCT using mobilized peripheral blood hematopoi-
etic stem cell products. Of these patients, 46 had pre-
transplantation FDG-PET performed following
salvage chemotherapy (n5 3 after 1 cycle, n5 28 after
2 cycles, n 5 9 after 3 cycles, n 5 1 after 4 cycles, and
n5 5 after an unknown number of cycles) with chemo-
sensitive disease and imaging available for blinded re-
view. Clinical and laboratory data were collected from
patient records, retrospectively. This study was ap-
proved by the Washington University School of Med-
icine institutional review board.FDG-PETand Prognostic Variables
Pre-ASCT FDG-PET images were retrieved from
digital archives and then blindly reviewed by experi-
enced nuclear medicine physicians (A.H., F.D.). The
FDG-PET was interpreted as positive or negative by
the International Harmonization Project established
criteria [11]. The FDG-PET studies were performed
at our institution with a Siemens Biograph Duo (Sie-
mens, Malvern, PA) or a Biograph-40 scanner follow-
ing our standard clinical protocol. The fasting glucose
was required to be\200 mg/dL immediately before
injection of 10-15 mCi (370-555 MBq) of FDG.
Thirty-one of the 46 patients had a spiral computed to-
mography (CT) scan (typically 95-111 effective mAs,
130 kvP, and 5-mm slice thickness) with oral, but not
intravenous, contrast followed by pelvis to skull-base
emission images. The PET emission images were
corrected for measured attenuation and reconstructed
using an ordered-subset estimation-maximization
(OSEM) iterative algorithm per the manufacturer’s in-
structions. Clinical and laboratory data were collected
from paper and electronic charts for the variables
included in these prognostic models: InternationalPrognostic Factors Project (IPFP) (anemia, hypoalbu-
minemia, lymphopenia, age) [14], German Relapsed
Hodgkin Prognostic Score (GRHS) (anemia, duration
of first remission, stage III/IV) [15], and Memorial
Sloan-Kettering Cancer Center model (MSKCC) (B
symptoms, presence of extra nodal disease, and dura-
tion of first remission) [16]. Each patient’s data was an-
alyzed for all 3 prognostic models, and a score for each
model was created by summation of the number of
pertinent variables present. When variables were un-
known, they were scored as absent (number of patients
affected by unknown data were IPFP: 7, GRHS: 2,
MSKCC: 0). Additional variables analyzed included
number of salvage chemotherapy regimens, response
to salvage chemotherapy, first remission duration of
\1 year, refractory disease, and prior use of radiation
therapy.
Statistical Analysis
The Kaplan-Meier method was used to estimate
event-free survival (EFS, time from ASCT until date
of relapse/progression or death) and overall survival
(OS, time from ASCT until date of death from any
cause). For both EFS and OS, patients were censored
at the last follow-up date. Individual prognostic vari-
ables (anemia, age, stage at relapse, refractory disease,
remission \1 year, presence of extra nodal disease,
B symptoms, number of salvage chemotherapies), indi-
vidual prognostic model scores for IPFP, GHRS,
MSKCC, and pre-ASCT FDG-PET response were
examined using the log-rank test to reveal any signifi-
cant influence on EFS or OS. Cox proportional haz-
ards method was adopted to further examine the
factors of interest identified in univariate analysis.
Hazard ratios (HRs) with 95% confidence intervals
(CIs) were calculated for those factors identified by
multivariate analysis and the IPFP, GRHS, and
MSKCC prognostic models. FDG-PET status
and clinical characteristic associations were examined,
and the results are shown in Table 1; because all vari-
ables were treated categorically, Pearson’s chi-square
or Fisher exact tests were used as appropriate. All sta-
tistical tests were 2-sided, with a significance level set
at .05, and calculated using SAS9.1 (SAS Institute
Inc., Cary, NC).RESULTS
Baseline patient demographic and prognostic fac-
tors for the patient cohort are shown in Table 1. The
median age was 36 (range: 18-70) years, with 26% of
patients age 45 years or older. Most patients received
doxorubicin, bleomycin, vinblastine, dacarbazine
(ABVD) or Stanford V frontline chemotherapy, and
etoposide, methylprednisolone, high-dose cytarabine,
cisplatin (ESHAP) or ifosfamide, carboplatin,
Table 1. Patient Characteristics
All Patients FDG-PET Negative FDG-PET Positive
Characteristic Value N % N % N % P Value
Gender .76
Female 19 46 9 47 10 53
Male 27 54 14 52 13 48
Age, years .74
Median (range) 37 (18-70)
#45 years 34 74 17 50 17 50
>45 years 12 26 6 50 6 50
Frontline therapy .35
ABVD 36 79 17 47 19 53
Stanford V 5 11 4 80 1 20
Other* 5 11 1 20 4 80
Salvage chemotherapy .27
ESHAP 19 41 8 42 11 58
ICE 15 33 6 40 9 60
GVD 5 11 3 60 2 40
Other† 6 13 5 83 1 16
ASCT conditioning 1.0
BEAM 45 98 22 49 23 51
BEAC 1 2 1 100 0 0
Stage at relapse
I 4 9 2 50 2 50
II 25 57 10 40 15 60
III 6 14 4 67 2 33
IV 9 20 5 56 4 44
Stage III or IV 15 33 9 60 6 40 .24
First remission <1 year 34 74 14 41 20 59 .04
B symptoms present‡ 19 46 10 52 9 48 .76
EN disease present‡ § 11 24 7 64 4 36 .30
Anemia present‡ 6 13 3 50 3 50 1.0
Albumin <4‡ 10 22 4 40 6 60 .36
Lymphopenia present‡ 5 11 2 40 3 60 1.0
ASCT indicates autologous stem cell transplanataion; FDG-PET, positron emission tomography using [18F]fluorodeoxyglucose.
*Other frontline regimens included: BEACOPP, MOPP, doxorubicin plus vinblastine.
†Other salvage regimens included: DHAP, MOPP, MOPP/ABV, EVA.
‡At relapse.
§Extranodal disease site: 4 bone, 5 lung, 1 pericardial, 1 bone marrow.
1648 Biol Blood Marrow Transplant 17:1646-1652, 2011J. P. Smeltzer et al.etoposide (ICE) at relapse. All but 1 patient underwent
carmustine, etoposide, cytarabine, melphalan (BEAM)
conditioning for ASCT, and all received peripheral
blood hematopoietic stem cell products.
All 46 patients had FDG-PET after salvage che-
motherapy before ASCT. The median time interval
(3 weeks, range: 1-10) from the completion of salvage
chemotherapy and FDG-PET was not statistically dif-
ferent for both FDG-PET positive (median 4 weeks)
and negative patients (median 3 weeks; P 5 0.27).
Pre-ASCT FDG-PET was positive in 23 patients
(50%) and negative in 23 patients (50%). Before trans-
plantation, 23 patients achieved a complete remission
(CR), 20 a partial remission (PR), and 3 patients had
stable disease (SD). Patients with SD were included
because they were deemed to have chemosensitive dis-
ease based on a decrease in size by FDG-PET that did
not formally qualify for PR. Because FDG-PET was
used for response assessment before ASCT, CR corre-
sponds to those patients with a negative FDG-PET;
additional independent contrast CT assessment was
not routinely performed. With an average follow uptime of 37.8 months, the 3-year EFS and OS rates
for all patients was 62% and 78%, respectively, with
5-year EFS andOS rates of 58% and 78%, respectively
(Figure 1).
Univariate analysis identified only pre-ASCT
FDG-PET as significantly associated with EFS. The
GRHS, IPFP, and MSKCC prognostic scoring sys-
tems were not significant in this patient cohort
(Table 2). The 3-year EFS rates were 82% and 41%
for patients whose FDG-PET was negative and posi-
tive, respectively (P 5 .02). The 3-year OS rates were
91% and 64% for patients whose FDG-PET was neg-
ative and positive, respectively (P 5 .08) (Figure 2).
Historic prognostic models (IPFP, GHRS,
MSKCC) were computed using the available clinical
and laboratory data. Although smaller in overall sam-
ple size, the score distribution of these models was sim-
ilar in our cohort when compared with previously
published studies [13,14]. The HR was calculated for
pre-ASCT FDG-PET in concert with these clinical/
laboratory-based prognostic models. Pre-ASCT
FDG-PET was found to be significant in predicting
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Figure 1. Overall EFS and OS for N 5 46 cHL patients in this study.
The 3 to 5-year EFS were 62%-58% and OS were 78%-78%.
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Biol Blood Marrow Transplant 17:1646-1652, 2011 1649Prognostic Significance of FDG-PETEFS with an HR of 3.2 (CI 1.1-9.0, P 5 .03). There
was a trend toward pre-ASCT FDG-PET predicting
OS with an HR of 3.6 (CI 0.75-17.5, P 5 .11). The
IPFP HR 1.77 (CI 0.97-3.24), GRHS HR 1.19
(CI 0.62-2.31), and MSKCC prognostic score HR
1.4 (CI 0.75-2.64) were not statistically significant in
predicting EFS (Table 2).0 12 24 36 48 60 72 84
0
Time (months)
Figure 2. EFS (A) and OS (B) for pre-ASCT PET-negative versus
positive patients.DISCUSSION
Risk stratification of relapsed cHL patients before
ASCT remains clinically important for prognostica-
tion and clinical trial design. We evaluated the ability
of pre-ASCT FDG-PET to predict clinically relevant
outcomes of EFS andOS in a relatively uniform cohort
of 46 relapsed patients treated with standard salvageTable 2. EFS Analyzed by Pre-ASCT FDG-PET Result and
Prognostic Scores
Prognostic Factor N % Hazard Ratio (95% CI) P Value
PET
Negative 23 50 3.2 (1.1-9.0) .02
Positive 23 50
GRHS 1.2 (0.62-2.3) .60
0 6 14
I 25 57
II 11 25
III 2 5
IPFP 1.7 (0.97-3.2) .06
0 21 54
I 13 33
II 4 10
III or IV 1 3
MSKCC 1.4 (0.75-2.6) .28
0 or I 27 58
II 15 33
III 4 9
GRHS indicates German Relapsed Hodgkin Prognostic Score; MSKCC,
Memorial Sloan-Kettering Cancer Center; IPFP, International Prognostic
Factors Project; FDG-PET, positron emission tomography using [18F]flu-
orodeoxyglucose; CI, confidence interval; ASCT, autologous stem cell
transplantation.therapy. Patients with a negative pre-ASCT FDG-
PET had a significantly superior 3-year EFS rate
(82%, P5 .02) compared with patients with a positive
pre-ASCTFDG-PET (41%). Similarly, those patients
with a negative pre-ASCT FDG-PET have an
improved 3-year OS rate (91%) compared with pa-
tients with a positive pre-ASCT FDG-PET (64%);
however, the difference in OS did not reach statistical
significance (P 5 .08). Because cHL patients who re-
lapse after ASCT transiently respond to a number of
different salvage approaches, including recent clinical
trials with novel agents [5], it is not surprising that
the difference in OS is not significant. These outcomes
suggest that relapsed cHL patients who receive stan-
dard salvage therapy and ASCT and have a negative
pre-ASCT FDG-PET enjoy a greater than 75%
chance of long-term, disease-free survival (DFS).
In contrast, approximately 40% of patients with
a positive pre-ASCT FDG-PET have long-term
DSF using this standard approach, indicating that
this group of patients remains heterogeneous in terms
of benefit from standard salvage therapy. Because 60%
of patients failed to have long-term benefit, this popu-
lation is appropriate to target for new therapeutic ap-
proaches. Notably, despite the overall inferior EFS
1650 Biol Blood Marrow Transplant 17:1646-1652, 2011J. P. Smeltzer et al.of pre-ASCT FDG-PET-positive patients, approxi-
mately 40% had long-term responses, suggesting
that a positive FDG-PET pre-ASCT is not adequate
to identify all patients who are destined to relapse. In
future clinical investigation, applying additional risk
stratification to pre-ASCT FDG-PET-positive pa-
tients will be important to separate those patients
who will fail to benefit from ASCT, so they could be
directed to themost appropriate experimental therapy.
It is important to note that our study and other studies
published to date [17-20] are retrospective and require
prospective validation.
Compared with older published studies with long-
term follow-up [10,21], the 3-year and 5-year OS and
EFS rates for our entire cohort was slightly improved.
Previous retrospective studies with large numbers of
relapsed cHL patients have identified a number of
prognostic factors and several models to predict
outcomes following ASCT [1]. In our 46 patients,
these previously published prognostic models (IPFP,
GRH, and MSKCC) were unable to predict EFS or
OS. Although our patients had a similar risk distribu-
tion as these studies, the smaller sample size likely
limited the power to detect modestly significant asso-
ciations with these models. However, the highly
significant disparity in outcomes based on pre-ASCT
FDG-PET suggest that this single imaging test may
be superior to pre-ASCT clinical and laboratory data
for prognostication.
Several retrospective studies have evaluated the
ability of pre-ASCT FDG-PET to predict outcomes
in relapsed cHL patients. Spaepen et al. [20] evaluated
nonattenuation corrected FDG-PET as a prognostic
factor pre-ASCT in 60 lymphoma patients, which in-
cluded a subset of n5 18 cHL patients. They reported
that 0/9 (0%) patients with a negative FDG-PET and
7/9 (77%) patients with a positive FDG-PET relapsed.
This yielded a statistically significant association be-
tween FDG-PET result and PFS (P\ .0025), but not
OS (P5 .13). The authors highlighted the preliminary
nature of the HL data because of the small number of
patient included in the study. Jabbour et al. [18] re-
ported on the ability of functional imaging (gallium
scans or FDG-PET) performed pre-ASCT to predict
PFS and OS in 211 cHL patients treated with ASCT
at MDACC from 1993 to 2004. Of the 211 patients,
68 had FDG-PET imaging performed. Seventy-two
percent (18 of 25) FDG-PET-positive patients and
23% (10 of 43) FDG-PET-negative patients relapsed,
but statistical comparison was not reported for the
FDG-PET subgroup. Combining the results of gal-
lium scans and FDG-PET, there was a statistically sig-
nificant association with PFS (P 5 .005) and a trend
with OS (P5 .059). Importantly, this group of patients
also received heterogeneous ASCT conditioning, with
significant differences in whether BEAM or another
conditioning regiment was used between FDG-PETpositive (26% BEAM) and FDG-PET negative pa-
tients (74% BEAM, P 5 .006). Because BEAM condi-
tioning was also associated with PFS (P 5 .0027) and
OS (P5 .007) inmultivariate analysis, these differences
could be a potential confounder in this report. This
study also demonstrated that functional imaging
(FDG-PET or gallium) provided better prognostica-
tion than standard CT, especially for patients with
a PR. Patients who were deemed PR by standard CT
assessment had significantly different 3-year PFS
(52% versus 27%) and OS (90% versus 65%), depend-
ing on their functional imaging results. In both of these
reports, currently accepted standard criteria to assess
lymphoma response were not used, and local interpre-
tation of positive and negative FDG-PETwas utilized.
In addition to these early studies, Castagana et al.
[17] reported the predictive results of FDG-PET per-
formed after 2 or 4 cycles of salvage chemotherapy
(pre-ASCT) in 24 relapsed HL patients treated from
2003 to 2007 with IGEV (ifosfamide, gemcitabine,
vinorelbine, prednisone) salvage chemotherapy. After
2 cycles of salvage, 9 of 10 (90%) FDG-PET positive
patients and 1 of 14 (7%) FDG-PET-negative patients
relapsed, which on univariate analysis revealed a signif-
icant association with PFS (P 5 .004) and OS (P 5
.024). Similarly, FDG-PET results were significantly
associated with PFS (P5 .001) and OS (P5 .003) after
4 cycles of IGEV therapy. Nomultivariate analysis was
included in this report. More recently, Moskowitz
et al. [19] reported on 153 relapsed/refractory cHL pa-
tients with chemosensitive disease who received an
ASCT from 1994 to 2003 in the context of clinical tri-
als at MSKCC assessed with functional imaging (gal-
lium scans or FDG-PET) pre-ASCT. Of these
patients, 42 (28%) had FDG-PET performed pre-
ASCT, and there was a significant association within
the FDG-PET subgroup and EFS (P 5 .003). For
the entire cohort that included both gallium and
FDG-PET results, functional imaging was the only
factor significantly associated with EFS and OS on
multivariate analysis. Thus, our results complement
these earlier studies by evaluating a homogenous pop-
ulation of 46 relapsed cHL patients, all with pre-
ASCT FDG-PET interpreted using IHP criteria,
treated with what is currently considered standard
therapy (Table 3).
How do these collective findings fit into current
clinical practice? Patients undergoing salvage chemo-
therapy should have a FDG-PET pre-ASCT, because
this provides the best current prognostic information,
based on multiple retrospective studies. When choos-
ing between conventional CT-based assessments and
FDG-PET in this context, retrospective studies have
demonstrated that functional imaging provides im-
proved prognostic information, especially for those
patients with a PR pre-ASCT [18]. For those patients
with positive FDG-PET after salvage chemotherapy,
Table 3. Summary of Published Studies Evaluating Pre-ASCT FDG-PETas a Prognostic Factor
Year Study
rel/ref cHL
pts (n)
IHP Criteria
Utilized
Patients with
PET (n)
Positive
Pre-ASCT
PET (n)
Negative
Pre-ASCT
PET (n)
EFS
(P Value)
OS
(P Value)
Multivariate
Analysis Ref
2003 Spaepen et al. 18 N 18 9 9 .025 .13 Y 21
2007 Jabbour et al. 211 N 68 43 25 NR NR Y 19
2009 Castagna et al. 24 Y 24 6 18 <.001 .003 N 18
2010 Moskowitz et al. 153 Y 42 NR NR .003 NR Y 20
2010 Current Study 106 Y 46 23 23 .02 .08 Y
rel/ref cHL indicates relapsed or refractory classical Hodgkin lymphoma; n, number; NR, not reported; IHP, international harmonization project; PET,
positron emission tomography; ASCT, autologous stem cell transplantation; EFS, event-free survival.
Biol Blood Marrow Transplant 17:1646-1652, 2011 1651Prognostic Significance of FDG-PETadditional standard dose therapy using an alternative
regimen may be considered based on single institution
studies [22], with the goal of obtaining a negative
FDG-PET pre-ASCT. Chemosensitive patients who
have a positive FDG-PET scan after salvage may ben-
efit from ASCT; however, only about 40% of patients
will have long-termDFS. Thus, clinical trials designed
to improve upon current second-line salvage therapy
with ASCT may be more informative if focused on
pre-ASCT FDG-PET-positive patients. For example,
additional ‘‘maintenance’’ therapy provided after
ASCT could potentially improve long-term outcomes
in this higher-risk group [23,24]. Alternatively, those
patients with positive pre-ASCT FDG-PET imaging
may consider an investigational therapy (eg, modifica-
tion of standard salvage chemotherapy). Such deci-
sions may be balanced by the number of promising
novel agents currently under evaluation for relapsed/
refractory cHL [5].ACKNOWLEDGMENTS
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